Development of a novel broad spectrum antifungal therapeutic targeting Glycosylphosphatidylinositol (GPI) biosynthesis and cell wall biogenesis

开发一种针对糖基磷脂酰肌醇 (GPI) 生物合成和细胞壁生物合成的新型广谱抗真菌治疗药物

基本信息

  • 批准号:
    10759723
  • 负责人:
  • 金额:
    $ 29.93万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-08-15 至 2025-07-31
  • 项目状态:
    未结题

项目摘要

Widespread azole resistance among Candida and Aspergillus spp. along with emerging echinocandin resistance in C. glabrata and C. auris raises the specter of untreatable multidrug resistant fungal infections, even as advances in medicine (cancer chemotherapy, organ transplant, premature infants, HIV/AIDS therapy) have increased the size of the vulnerable population. Our proposal aims to develop a novel broad spectrum antifungal therapeutic targeting Glycosylphosphatidylinositol (GPI) biosynthesis to treat life threatening infections due to drug resistant Candida and Aspergillus with no cross resistance to existing agents. Our Aims are: Aim 1 (Phase 1). Demonstrate improved efficacy is achievable by optimizing pharmacokinetic (PK) properties of the series. Perform metabolic identification (MetID) studies on M743, M720, and the hydrolyzed core lacking the sidechain to identify oxidative metabolic hotspots to guide a limited Lead Optimization (Lead Opt) effort to improve PK properties of the series while maintaining potency, spectrum, target selectivity, and minimizing cytotoxicity. Test up to 2 new analogs in a murine systemic infection model of Candidiasis with and without 1-aminobenzotriazole (ABT) PK enhancer codosing. Milestone 1. Based on MetID studies, synthesize up to 30 new M743 analogs. An analog showing an IP-administered dose-dependent > 3 log10 reduction in fungal burden in a murine Candidiasis model (i.e. superior to M720 efficacy) with or without ABT codosing will identify the key (and addressable) liability of the series and warrant advancement of the program to Ph 2. Aim 2 (Phase 2). M743 scale up, Lead Opt and in vitro characterization of compounds. Produce M743 on scale sufficient to supply a full Lead Opt effort based on MetID data and emerging SAR. Characterize analogs as in Aim 1 with additional emphasis on PK, MOA, reduced serum binding, and cytotoxicity. Milestone 2. Obtain 3g of M743; semisynthesize up to 100 new analogs. Identify up to 3 analogs with acceptable potency and PK (without ABT codosing), along with validated target engagement, FOR <1 x 109, in vitro synergy with Gwt1 inhibitor, APX001A (FICI<0.5), progressible activity in serum, and acceptable toxicity (in vivo cytotoxicity vs. HepG2, in vitro IC50>10 uM vs ion channels, CYPs, critical PANLABS targets) to advance to Aim 3. Aim 3 (Phase 2). In vivo Characterization. Efficacy of up to 2 compounds will be tested in a murine Candidiasis (including codosing with APX001 to evaluate in vivo synergy) and Invasive Pulmonary Aspergillosis infection models without ABT codosing. Milestone 3. Semisynthesize 200 mg of each test compound. Demonstrate acceptable MIC90 across Candida/Aspergillus spp. Identify suitable formulation for IP dosing. Conduct dose-ranging studies to gauge exposures and tolerability at higher doses to guide dose selection. Top analog achieving dose-dependent efficacy in each infection model (> 3 log reduction in burden over therapeutic duration) and overall favorable drug-like properties will be selected as a preclinical candidate.
念珠菌和曲霉属中广泛存在唑类耐药性。以及新兴的棘白菌素 光滑念珠菌和耳念珠菌的耐药性引发了无法治疗的多重耐药真菌感染的担忧, 即使医学不断进步(癌症化疗、器官移植、早产儿、艾滋病毒/艾滋病治疗) 增加了弱势群体的规模。我们的建议旨在开发一种新颖的广谱 针对糖基磷脂酰肌醇 (GPI) 生物合成的抗真菌治疗可治疗危及生命的疾病 耐药念珠菌和曲霉菌引起的感染,与现有药物没有交叉耐药性。我们的 目标是: 目标 1(第一阶段)。证明通过优化药代动力学 (PK) 可以提高疗效 该系列的属性。对 M743、M720 和水解产物进行代谢鉴定 (MetID) 研究 缺乏侧链的核心无法识别氧化代谢热点,从而指导有限的先导优化(Lead Opt) 努力改善该系列的 PK 特性,同时保持效力、谱图、目标选择性和 最大限度地减少细胞毒性。在鼠念珠菌病全身感染模型中测试多达 2 种新的类似物 无需 1-氨基苯并三唑 (ABT) PK 增强剂共同给药。里程碑 1. 基于 MetID 研究,综合 多达 30 个新的 M743 类似物。类似物显示 IP 给药剂量依赖性 > 3 log10 减少 鼠念珠菌病模型中的真菌负荷(即优于 M720 功效),无论是否联合给药 ABT 确定该系列的关键(和可解决的)责任,并保证该计划推进到第二阶段。 目标 2(第 2 阶段)。 M743 放大、Lead Opt 和化合物的体外表征。生产M743 规模足以提供基于 MetID 数据和新兴 SAR 的全面先导选择工作。表征 与目标 1 中的类似物,额外强调 PK、MOA、降低的血清结合和细胞毒性。里程碑 2、获得M743 3g;半合成多达 100 种新类似物。鉴定最多 3 个具有可接受效力的类似物 和 PK(无 ABT 联合给药),以及经过验证的靶点参与,FOR <1 x 109,体外协同作用 Gwt1抑制剂,APX001A(FICI<0.5),血清中的渐进活性,以及​​可接受的毒性(体内细胞毒性) 与 HepG2 相比,体外 IC50>10 uM(与离子通道、CYP、关键 PANLABS 目标相比),以推进目标 3。 目标 3(第 2 阶段)。体内表征。最多 2 种化合物的功效将在小鼠身上进行测试 念珠菌病(包括与 APX001 共同给药以评估体内协同作用)和侵袭性肺部疾病 无需 ABT 联合给药的曲霉菌感染模型。里程碑 3. 每个测试半合成 200 mg 化合物。在念珠菌/曲霉属中表现出可接受的 MIC90。确定合适的 IP 配方 剂量。进行剂量范围研究,以评估较高剂量下的暴露和耐受性,以指导剂量 选择。顶级类似物在每种感染模型中实现剂量依赖性功效(负担减少> 3 log 超过治疗持续时间)和总体有利的药物样特性将被选择作为临床前候选药物。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Terry Roemer其他文献

Terry Roemer的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Terry Roemer', 18)}}的其他基金

Development of a mechanistically novel synergistic adjuvant to partner with polymyxin antibiotics
开发一种与多粘菌素抗生素配合使用的新型机械协同佐剂
  • 批准号:
    10481682
  • 财政年份:
    2022
  • 资助金额:
    $ 29.93万
  • 项目类别:
Development of a mechanistically novel Gram-negative antibiotic targeting MsbA-mediated Lipopolysaccharide Biogenesis
开发一种机制新颖的革兰氏阴性抗生素,靶向 MsbA 介导的脂多糖生物发生
  • 批准号:
    10584170
  • 财政年份:
    2022
  • 资助金额:
    $ 29.93万
  • 项目类别:
Characterization of MsbA inhibitors as potential antibiotic leads to treat carbapenem-resistant Enterobacteriaceae (CRE)
MsbA 抑制剂作为潜在抗生素的特性可用于治疗耐碳青霉烯类肠杆菌 (CRE)
  • 批准号:
    10242174
  • 财政年份:
    2020
  • 资助金额:
    $ 29.93万
  • 项目类别:
Characterization of MsbA inhibitors as potential antibiotic leads to treat carbapenem-resistant Enterobacteriaceae (CRE)
MsbA 抑制剂作为潜在抗生素的特性可用于治疗耐碳青霉烯类肠杆菌 (CRE)
  • 批准号:
    9978345
  • 财政年份:
    2020
  • 资助金额:
    $ 29.93万
  • 项目类别:
Development of WecA-targeting immune potentiators to treat carbapenem-resistant Enterobacteriaceae (CRE) infections
开发 WecA 靶向免疫增强剂来治疗碳青霉烯类耐药肠杆菌 (CRE) 感染
  • 批准号:
    10415522
  • 财政年份:
    2019
  • 资助金额:
    $ 29.93万
  • 项目类别:
Development of WecA-targeting immune potentiators to treat carbapenem-resistant Enterobacteriaceae (CRE) infections
开发 WecA 靶向免疫增强剂来治疗碳青霉烯类耐药肠杆菌 (CRE) 感染
  • 批准号:
    10470327
  • 财政年份:
    2019
  • 资助金额:
    $ 29.93万
  • 项目类别:
Development of a novel agent to treat antimicrobial resistant Neisseria gonorrhoeae
开发治疗耐药性淋病奈瑟菌的新型药物
  • 批准号:
    9620389
  • 财政年份:
    2018
  • 资助金额:
    $ 29.93万
  • 项目类别:
Restoring Beta-lactam efficacy against methicillin-resistant Staphylococci
恢复 β-内酰胺对耐甲氧西林葡萄球菌的功效
  • 批准号:
    9814432
  • 财政年份:
    2018
  • 资助金额:
    $ 29.93万
  • 项目类别:
Development of a PO-administered beta-lactam-tarocin combination agent to treat methicillin susceptible and methicillin resistant Staphylococci
开发用于治疗甲氧西林敏感和甲氧西林耐药葡萄球菌的 PO 给药 β-内酰胺-塔罗辛组合药物
  • 批准号:
    10662488
  • 财政年份:
    2018
  • 资助金额:
    $ 29.93万
  • 项目类别:
Development of a PO-administered beta-lactam-tarocin combination agent to treat methicillin susceptible and methicillin resistant Staphylococci
开发用于治疗甲氧西林敏感和甲氧西林耐药葡萄球菌的 PO 给药 β-内酰胺-塔罗辛组合药物
  • 批准号:
    10547079
  • 财政年份:
    2018
  • 资助金额:
    $ 29.93万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 29.93万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 29.93万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 29.93万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 29.93万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 29.93万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 29.93万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 29.93万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 29.93万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 29.93万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 29.93万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了